Sydney Medical School

GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, August 31, 2022
Patient, COVID-19, University, Ecolab, Government, Sydney Medical School, Doctor of Philosophy, Exercise, Intelligence, R, GBS, Interim, Pacific Northwest Diabetes Research Institute, Board, Blood, IPO, Audit committee, University of Sydney, MPMC, Organization, Comparison, NEW, Financial compensation, GLOBE, Â, Fluorescent glucose biosensor, IFP, Nasdaq, Company, Saliva, Commercialization, Committee, ET, Webcast, Director, Acquisition, Chemical engineer, Clinical, Trial of the century, Development, Professional Football Compensation Committee, Income, Medical device, Video game, Management, Sand, Medical imaging, Research, Operation

NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time monitoring and diagnostic testing for patients and their primary health practitioners at point of care, today announced its preliminary financial results for the fourth financial quarter and full-year ended June 30, 2022 and provided a business update. Management will host a webcast and conference call at 4:30 p.m. ET today.

Key Points: 
  • ET -
    NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time monitoring and diagnostic testing for patients and their primary health practitioners at point of care, today announced its preliminary financial results for the fourth financial quarter and full-year ended June 30, 2022 and provided a business update.
  • We continue our thorough due diligence process and remain on track to update the market in the near term.
  • GBS is now proceeding with the next phase of the glucose biosensor development program, including two key parallel clinical studies.
  • Employee Benefits Expense for the full fiscal year 2022 of $2.3 million compared to the year prior of $1.9 million.

Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS/MND

Retrieved on: 
Friday, December 10, 2021
Massachusetts General Hospital, Risk, Patient, HIV disease progression rates, ALS, SALT, Leg, Medulla oblongata, Amyotrophic lateral sclerosis, Gastrostomy, Population, NASDAQ, Sean, Hospital, International Symposium on Graph Drawing, Neurodegeneration, Hand, Concord Repatriation General Hospital, Pharmacokinetics, Muscle, Sydney Medical School, Arm, Concord Hospital, CNM, Safety, Association, Motor neuron, Death, Ventilation, Tracheotomy, Quality of life, Massachusetts, Week, University, Survival, GLOBE, Pharmaceutical industry, Silviculture

At the late-breaking session, Professor Steve Vucic will present RESCUE-ALS study results that were supportive of CNM-Au8 efficacy for clinically meaningful functional endpoints in an early ALS population.

Key Points: 
  • At the late-breaking session, Professor Steve Vucic will present RESCUE-ALS study results that were supportive of CNM-Au8 efficacy for clinically meaningful functional endpoints in an early ALS population.
  • Significant improvement in quality of life as measured by ALS specific quality of life short form.
  • CNM-Au8 was well tolerated and safe with no drug related serious adverse events or drug discontinuations.
  • RESCUE-ALS showed that CNM-Au8 significantly slowed disease progression, functional decline, improved quality of life, and prolonged survival in ALS patients.

Clene Nanomedicine’s RESCUE-ALS Phase 2 Results Selected for Late-Breaking Presentation at 32nd International Symposium on ALS/MND

Retrieved on: 
Tuesday, December 7, 2021
Central nervous system, Twitter, Risk, MND, Traffic barrier, Research, Neurology, Population, GLOBE, Conference, Pharmacokinetics, Reactive oxygen species, Hand, Gold, Multiple sclerosis, Safety, Silver, SALT, Quality of life, Neurodegeneration, Brain, Patient, Motor neuron, Sydney Medical School, CNM, International Symposium on Endovascular Therapy, Neuroprotection, R, Neuron, HIV disease progression rates, MS, CNS, Arm, Leg, Remyelination, Nanoparticle, University, Survival, Toxic leukoencephalopathy, NASDAQ, LinkedIn, ALS, Association, PD, Medulla oblongata, Muscle, Lists of diseases, Pharmaceutical industry

A live poster session will be presented during the above designated time where attendees can chat live with the presenter.

Key Points: 
  • A live poster session will be presented during the above designated time where attendees can chat live with the presenter.
  • This years virtual symposium will take place on December 7 - 10, 2021.
  • RESCUE-ALS, a Phase 2 multi-center, randomized, double-blind, parallel-group, placebo-controlled trial examined the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in patients with early amyotrophic lateral sclerosis (ALS).
  • Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.

GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing

Retrieved on: 
Monday, November 1, 2021
Program, University of Sydney, Twitter, Organization, U.S. Securities and Exchange Commission, Terminology, Interim, Board for International Food and Agricultural Development (BIFAD), Policy, Ministry of Health (New South Wales), GBS, Oklahoma Homeland Security Act, Westmead Hospital, GLOBE, Doctor of Philosophy, Securities Exchange Act of 1934, Center, Research, Iodine, Security (finance), Private Securities Litigation Reform Act, Central Training Institute Jabalpur, University, Company, Sydney Medical School, Health, Biotechnology, Medical director, Sydney South West Area Health Service, Leadership, Medicine, CETI, Clinical professor, AUD, Nasdaq, Population, Securities Act of 1933, LinkedIn, Endocrinology, Patient, Growth hormone, Forward-looking statement, Board, Management

In order to bolster the Companys existing management capabilities, the Board is implementing a number of leadership and management changes.

Key Points: 
  • In order to bolster the Companys existing management capabilities, the Board is implementing a number of leadership and management changes.
  • The Board is initiating a search process with a leading executive search firm to identify a permanent CEO.
  • Additionally, the Board announced that Harry Simeonidis, will continue to serve GBS now as President Asia Pacific, Sales & Marketing.
  • I am honored to take on the role of interim CEO during this important time of development for the Company, said Steven Boyages Chief Executive Officer of GBS.

Philips installs leading digital imaging solutions at new Central Acute Services Building of Westmead Hospital in Sydney Australia

Retrieved on: 
Monday, April 19, 2021
Sydney Medical School, Westmead Hospital, Philips, Westmead, Radiology, Companies, Brands, Consumer electronics

b'New state-of-the-art Central Acute Services Building at Westmead Hospital features next-generation diagnostic and neurovascular imaging solutions, aimed at improving the efficiency and accuracy of care delivered to trauma patients requiring critical care\nAmsterdam, the Netherlands and Sydney Australia \xe2\x80\x93 Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the successful installation of its most advanced digital diagnostic and interventional neurovascular imaging solutions in the brand new Central Acute Services Building at Westmead Hospital (Sydney, Australia).

Key Points: 
  • b'New state-of-the-art Central Acute Services Building at Westmead Hospital features next-generation diagnostic and neurovascular imaging solutions, aimed at improving the efficiency and accuracy of care delivered to trauma patients requiring critical care\nAmsterdam, the Netherlands and Sydney Australia \xe2\x80\x93 Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the successful installation of its most advanced digital diagnostic and interventional neurovascular imaging solutions in the brand new Central Acute Services Building at Westmead Hospital (Sydney, Australia).
  • Part of a sterile dual-room concept that offers an operating suite directly connected to a scanning room, the MR-OR systems will provide MR imaging during neurosurgery.
  • This will help enable closer collaboration between surgeons and radiologists, delivering greater speed, efficiency and clinical confidence.
  • In addition to Philips Magnetic Resonance \xe2\x80\x93 Ingenia MR-OR \xe2\x80\x93 and Image Guided Therapy System \xe2\x80\x93 Azurion biplane \xe2\x80\x93, Philips has also provided Westmead Hospital\xe2\x80\x99s Central Acute Services Building with:\n'